JPMorgan Chase & Co. Has $613,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

JPMorgan Chase & Co. reduced its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAKFree Report) by 25.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 43,105 shares of the company’s stock after selling 14,599 shares during the period. JPMorgan Chase & Co.’s holdings in Takeda Pharmaceutical were worth $613,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB acquired a new position in Takeda Pharmaceutical in the third quarter worth $40,000. BNP Paribas Financial Markets increased its holdings in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after purchasing an additional 2,596 shares in the last quarter. Smithfield Trust Co raised its position in Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares during the last quarter. Erste Asset Management GmbH acquired a new position in Takeda Pharmaceutical during the 3rd quarter worth $52,000. Finally, Hexagon Capital Partners LLC boosted its position in Takeda Pharmaceutical by 34.3% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after buying an additional 1,129 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Takeda Pharmaceutical stock opened at $13.35 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 12-month low of $12.57 and a 12-month high of $15.08. The stock has a market cap of $42.46 billion, a price-to-earnings ratio of 23.01, a P/E/G ratio of 0.24 and a beta of 0.51. The business’s 50-day simple moving average is $13.31 and its 200 day simple moving average is $13.89.

Takeda Pharmaceutical Company Profile

(Free Report)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.

Featured Articles

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAKFree Report).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.